A Clinical Study on the Efficacy and Safety of ABCD in the Treatment of Patients With Invasive Fungal Disease

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

September 30, 2025

Conditions
Invasive Fungal Disease
Interventions
DRUG

Amphotericin B cholesterol-sulfate complex for injection

"Patients were eligible for enrollment on antifungal therapy with injectable amphotericin B cholesterol-sulfate complex (ABCD) at the same time as a treatment for underlying disease.~Dosage: According to the patient's condition and the investigator's judgment, the initial dose of ABCD can be 0.5-1.0mg/kg/d, and the dose can be increased daily according to the situation, and the therapeutic dose can be increased to 3.0-4.0mg/kg/d on the third day.~Course of treatment: ≥ 14 days (whether to continue to receive trial drug treatment after 14 days is decided by the investigator according to the patient's condition)."

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT06376201 - A Clinical Study on the Efficacy and Safety of ABCD in the Treatment of Patients With Invasive Fungal Disease | Biotech Hunter | Biotech Hunter